Sanofi acquisition of Kymab : French pharma giant Sanofi has signed a deal worth up to $1.45 billion to acquire Kymab, a UK-based clinical-stage biopharma company focused on developing fully human monoclonal antibodies, particularly for immune-mediated diseases, and immuno-oncology therapeutics. The consideration includes an upfront payment of around $1.1 billion and up to $350 million […]
Novartis acquisition of Cadent Therapeutics : Swiss pharma giant Novartis has agreed to acquire a US neuroscience company Cadent Therapeutics, in a deal worth up to $770 million. The consideration includes an upfront payment of $210 million and up to $560 million in milestone payments. Cadent Therapeutics was launched about three years ago via the […]
Continue reading …Eli Lilly and Company (Lilly) has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a US gene therapy company engaged in developing disease-modifying AAV9-based gene therapies for neurodegenerative diseases. According to the US pharma giant, the acquisition will set up a new modality for drug discovery and development. It will also […]
Continue reading …Swedish private equity company EQT Partners has offered to takeover Recipharm, a Swedish pharma contract development and manufacturing organization (CDMO), for SEK 23.6 billion ($2.82 billion). As per the terms of the offer, Recipharm’s shareholders are being offered SEK 220 ($26.3) in cash for each of its class B shares EQT IX, a fund managed […]
Continue reading …AstraZeneca acquisition of Alexion Pharmaceuticals : Pharma giant AstraZeneca has signed a $39 billion deal to acquire Alexion Pharmaceuticals, a US biopharma company engaged in developing therapies for rare disorders. As per the terms of the deal, Alexion Pharmaceuticals’ shareholders will be paid $60 in cash and 2.1243 American Depositary Shares (ADSs) of AstraZeneca, valuing […]
Continue reading …Gilead Sciences acquisition of MYR : US biopharma giant Gilead Sciences has agreed to acquire MYR, a German biotech company engaged in developing therapies for chronic hepatitis delta virus (HDV), in a deal worth up to €1.45 billion. The consideration consists of nearly €1.15 billion in cash, which will be paid at the time of […]
Continue reading …German pharma company Boehringer Ingelheim has signed a deal worth €1.18 billion to acquire NBE-Therapeutics, a clinical-stage Switzerland-based biotech company, focused on developing antibody-drug conjugates (ADCs) and advancing targeted cancer therapies. Through the acquisition, Boehringer Ingelheim will gain access to the Swiss firm’s iADC platform, which is capable of creating immune stimulatory ADCs with an […]
Continue reading …Merck acquisition of OncoImmune : Pharma giant Merck has signed an all-cash deal worth $425 million to acquire OncoImmune to gain access to the latter’s investigational Covid-19 drug – CD24Fc. Based in Maryland, OncoImmune is a clinical-stage biopharma company, that is focused on the discovery and development of therapies for cancer and autoimmune disease. As […]
Continue reading …Bristol Myers Squibb has wrapped up its previously announced $13.1 billion acquisition of MyoKardia, a California-based clinical-stage biopharma company. Following the closing of the deal, the shares of MyoKardia have ceased trading on the NASDAQ Global Select Market and the company is now a fully-owned subsidiary of Bristol Myers Squibb. As per the terms of […]
Continue reading …Merck acquisition of VelosBio : US pharma giant Merck has agreed to acquire VelosBio, a California-based clinical-stage biopharma company, for $2.75 billion in an all-cash deal, in a move to strengthen its oncology pipeline. VelosBio is engaged in developing cancer therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1). The company’s lead investigational candidate […]
Continue reading …